Oncoinvent ASA (OSL:ONCIN)
48.70
+1.30 (2.74%)
May 13, 2026, 4:25 PM CET
Oncoinvent ASA Revenue
In the year 2025, Oncoinvent ASA had annual revenue of 28.07M NOK with 246.40% growth. Oncoinvent ASA had revenue of 16.11M in the half year ending December 31, 2025, with 192.20% growth.
Revenue
28.07M
Revenue Growth
+246.40%
P/S Ratio
7.77
Revenue / Employee
637.93K
Employees
44
Market Cap
218.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.07M | 19.97M | 246.40% |
| Dec 31, 2024 | 8.10M | 2.31M | 39.95% |
| Dec 31, 2023 | 5.79M | -493.00K | -7.85% |
| Dec 31, 2022 | 6.28M | -4.80M | -43.31% |
| Dec 31, 2021 | 11.08M | 705.85K | 6.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 128.37M |
| Arctic Bioscience AS | 42.62M |
| SoftOx Solutions AS | 15.58M |
| Aqua Bio Technology ASA | 7.53M |
| Nykode Therapeutics AS | 4.57M |
| Thor Medical ASA | 839.00K |
| Lytix Biopharma ASA | 377.00K |
| Circio Holding ASA | 123.00K |
Oncoinvent ASA News
- 16 days ago - Oncoinvent ASA Earnings Call Transcript: Q1 2026 - Transcripts
- 16 days ago - Oncoinvent ASA Transcript: Investor update - Transcripts
- 2 months ago - Oncoinvent ASA Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Oncoinvent ASA: Second half 2025 results - PRNewsWire
- 4 months ago - Oncoinvent ASA Transcript: EGM 2026 - Transcripts
- 5 months ago - Oncoinvent ASA Transcript: EGM 2025 - Transcripts
- 6 months ago - Oncoinvent ASA Earnings Call Transcript: Q3 2025 - Transcripts
- 11 months ago - Oncoinvent ASA Transcript: M&A Announcement - Transcripts